Petwealth Raises $1.7M to Bring Clinical-Grade At-Home PCR Diagnostics to Pet Care
Founder stories usually get polished for the pitch deck. This one didn’t need polishing. Angelo P. Palivos built Petwealth after losing his dog Mochi to something that could have been caught earlier. No theatrics, no overproduction, just a problem that forced a sharper answer.
Now Petwealth steps out of stealth with $1.7M raised, planting a flag in a part of the market that’s been running on instinct a little too long. Clinical-grade PCR diagnostics, the same standard trusted in human health, shipped directly to pet owners’ homes. 100+ markers across gut, oral, and respiratory health, with results in under 48 hours. Not theoretical. Operational.
Zoë Barry and Angelo P. Palivos are building more than a product line. This is infrastructure taking shape. While much of pet care still reacts after symptoms show up, Petwealth is positioning itself earlier in the timeline, where detection carries leverage. Kennel Connection extends that reach into more than 5,500 locations, embedding diagnostics into daily workflows instead of occasional check-ins. Pawp connects the output to telehealth, turning test results into immediate clinical context.
The delivery looks simple by design. A kit arrives. A sample goes out. Underneath sits molecular testing paired with a data interpretation layer that translates raw results into something usable. The Petwealth Pack lands at $399, with individual panels at $175, a structure that signals both bundled adoption and targeted use cases without drifting into commodity pricing.
What’s unfolding here is less about convenience and more about timing. Pet care has historically leaned reactive, shaped by visible symptoms and periodic visits. Moving diagnostics upstream introduces consistency, and consistency tends to reshape behavior. When testing becomes routine, the definition of “early” starts to change.
Predictive, Founders Future, Generous Ventures, and NOA Capital show up early on this one, backing a friends and family round that sits ahead of a broader pre-seed push. No lead investor named, which makes the alignment here worth watching rather than glossing over.
Petwealth enters the market without much noise, but with clear placement. Diagnostics at home, integrated across software and telehealth, positioned as a layer rather than a feature. The kind of move that doesn’t ask for attention, but tends to accumulate it anyway.
